Ardelyx, Inc.

📍 Waltham, United States🗓 Founded 2007👥 478 employees💰 Last funded Sep 2024
Biotechnology Research🌐 ardelyx.com
Website LinkedIn
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of tenapanor for chronic idiopathic constipation, and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Community Guidelines: https://rb.gy/07ltg3
3
Total investors
0
Early stage
1
Mid stage
1
Late stage
2007
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Liechtenstein
1
Investor activity2011–2024 · investors recorded per year
201112015120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Ardelyx, Inc.?
Ardelyx, Inc. has 3 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Ardelyx, Inc. last raise funding?
The most recent investment in Ardelyx, Inc. recorded on gritt.io was in September 2024.
When was Ardelyx, Inc. founded?
Ardelyx, Inc. was founded in 2007.
What industry is Ardelyx, Inc. in?
Ardelyx, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ardelyx, Inc. based?
Ardelyx, Inc. is headquartered in Waltham, United States.